Approval Significantly Expands Production Capacity for ImClone’s Proprietary Pipeline Antibodies

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that it has received approval from the Food and Drug Administration for its state-of-the-art “BB50” manufacturing facility to manufacture multiple products. This approval significantly expands ImClone’s total available production volume capacity for its proprietary pipeline of novel antibodies, which are now entering late-stage clinical development.

“This multi-product FDA approval of BB50 significantly enhances ImClone’s operational flexibility as we scale up production of our robust pipeline of proprietary antibodies for the growing number of Phase 2 and Phase 3 trials that will be commencing in the next year,” said Richard P. Crowley, Senior Vice President, Biopharmaceutical Operations of ImClone. “ImClone has one of the largest biologic production capacities in the world and this approval is an important milestone in our efforts to maximize the global potential of both ERBITUX® and our portfolio of novel fully-human antibodies, which together represents one of the deepest pipelines in oncology today.”

ImClone’s 250,000-square-foot multi-suite BB50 facility received FDA approval to manufacture ERBITUX (cetuximab) in August 2007. Together with the Company’s “BB36” manufacturing facility, ImClone has a total production volume capacity of up to 140,000 liters at its Branchburg, N.J. campus. This is among the largest antibody manufacturing capacities in the biotechnology industry and is a key component of ImClone’s fully integrated operations supporting the development and commercialization of the Company’s antibodies.

ImClone’s Proprietary Pipeline Antibodies

ImClone has established one of the deepest pipelines in oncology therapeutics. In addition to the blockbuster cancer drug ERBITUX, ImClone has a robust pipeline of proprietary monoclonal antibodies in clinical development. The Company is developing these pipeline antibodies with the hope of optimizing efficacy and safety by targeting specific tumor receptors, by developing fully human antibodies, and by developing IgG1 antibodies which may have the potential to increase efficacy through an antibody cell-mediated cytotoxicity.